gemadol retard 100 mg depotkapsler
viatris aps - tramadolhydrochlorid - depotkapsler - 100 mg
gemadol retard 150 mg depotkapsler
viatris aps - tramadolhydrochlorid - depotkapsler - 150 mg
gemadol retard 200 mg depotkapsler
viatris aps - tramadolhydrochlorid - depotkapsler - 200 mg
metronidazol "dak" 500 mg filmovertrukne tabletter
orifarm healthcare a/s - metronidazol - filmovertrukne tabletter - 500 mg
pyrazinamid "medic" 500 mg tabletter
mylan denmark aps - pyrazinamidum - tabletter - 500 mg
uniloc 100 mg tabletter
takeda pharma a/s - atenolol - tabletter - 100 mg
uniloc 25 mg tabletter
takeda pharma a/s - atenolol - tabletter - 25 mg
uniloc 50 mg tabletter
takeda pharma a/s - atenolol - tabletter - 50 mg
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiske midler - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
lenalidomide accord
accord healthcare s.l.u. - lenalidomid - multipelt myelom - immunosuppressiva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, der ikke er berettiget til transplantation. lenalidomid overenskomst i kombination med dexamethason er indiceret til behandling af myelomatose hos voksne patienter, der har modtaget mindst én tidligere behandling. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).